AXSOME THERAPEUTICS ($AXSM) is expected to release its quarterly earnings data on Monday, August 10th before market open, per Finnhub. Analysts are expecting revenue of $225,452,303 and earnings of -$0.86 per share.

You can see Quiver Quantitative's $AXSM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

AXSOME THERAPEUTICS Insider Trading Activity

AXSOME THERAPEUTICS insiders have traded $AXSM stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.

Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:

• HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 2 sales selling 99,336 shares for an estimated $23,903,223.
• MARK COLEMAN has made 0 purchases and 5 sales selling 43,180 shares for an estimated $8,207,327.
• NICK PIZZIE (Chief Financial Officer) sold 33,000 shares for an estimated $7,922,970
• MARK L. JACOBSON (Chief Operating Officer) has made 0 purchases and 3 sales selling 40,128 shares for an estimated $6,809,761.
• ARI MAIZEL (Chief Commercial Officer) sold 7,500 shares for an estimated $1,368,150
• SUSAN MAHONY has made 0 purchases and 2 sales selling 600 shares for an estimated $145,017.
• ROGER JEFFS has made 0 purchases and 2 sales selling 572 shares for an estimated $141,655.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

AXSOME THERAPEUTICS Hedge Fund Activity

We have seen 218 institutional investors add shares of AXSOME THERAPEUTICS stock to their portfolio, and 192 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• RTW INVESTMENTS, LP removed 888,001 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $150,089,929
• BLACKROCK, INC. removed 809,136 shares (-20.7%) from their portfolio in Q2 2026, for an estimated $198,052,218
• FIRST TRUST ADVISORS LP added 534,066 shares (+1230.2%) to their portfolio in Q1 2026, for an estimated $90,267,835
• ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 414,419 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $70,045,099
• ASSENAGON ASSET MANAGEMENT S.A. removed 411,276 shares (-47.5%) from their portfolio in Q2 2026, for an estimated $100,668,026
• POINT72 ASSET MANAGEMENT, L.P. added 406,751 shares (+2259.9%) to their portfolio in Q1 2026, for an estimated $68,749,054
• FMR LLC added 385,373 shares (+32.6%) to their portfolio in Q1 2026, for an estimated $65,135,744

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

AXSOME THERAPEUTICS Price Targets

Multiple analysts have issued price targets for $AXSM recently. We have seen 12 analysts offer price targets for $AXSM in the last 6 months, with a median target of $263.5.

Here are some recent targets:

• Raghuram Selvaraju from HC Wainwright & Co. set a target price of $290.0 on 07/08/2026
• Leonid Timashev from RBC Capital set a target price of $304.0 on 07/07/2026
• Joseph Thome from TD Cowen set a target price of $300.0 on 06/17/2026
• Ami Fadia from Needham set a target price of $267.0 on 05/05/2026
• Joel Beatty from Baird set a target price of $246.0 on 05/05/2026
• Benjamin Burnett from Wells Fargo set a target price of $255.0 on 05/05/2026
• Yatin Suneja from Guggenheim set a target price of $260.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

Read full article here »